Form 4: Atai Beckley Director Boosts Stake Post-Acquisition

Atai Beckley N.V. Director Cosmo Feilding-Mellen reported significant share and option acquisitions following the completion of the Beckley Psytech acquisition.

Summary

• Cosmo Feilding-Mellen, a Director and 10% Owner of Atai Beckley N.V., reported changes in beneficial ownership.
• The report details the acquisition of 7,702,990 common shares and 143,400 stock options (103,000 + 40,400) on November 5, 2025.
• These transactions are linked to the completion of Atai's previously announced acquisition of the entire issued share capital of Beckley Psytech Limited not already owned by Atai.
• In connection with the acquisition, Atai issued an aggregate of 103,000,066 common shares as share consideration or underlying replacement awards.
• The stock options have an exercise price of $4.48.
• One tranche of 103,000 stock options vests in full on the first anniversary of the grant date (November 5, 2025).
• Another tranche of 40,400 stock options vests in 12 substantially equal monthly installments, beginning December 5, 2025.

Sentiment

Score: 7

Explanation: The completion of a previously announced acquisition and a significant increase in beneficial ownership by a director and 10% owner are generally viewed positively, indicating confidence and strategic execution, despite the dilutive effect of share issuance for the acquisition.

Positives

• Completion of the previously announced acquisition of Beckley Psytech Limited, consolidating ownership and potentially strengthening Atai's market position.
• A Director and 10% Owner, Cosmo Feilding-Mellen, increased his beneficial ownership in Atai Beckley N.V. by acquiring 7,702,990 common shares and 143,400 stock options, indicating confidence in the company's future.

Future Outlook

The acquired stock options have specific vesting schedules: 103,000 options will vest in full on November 5, 2026, and 40,400 options will vest in 12 equal monthly installments starting December 5, 2025, with an expiration date of November 5, 2035.

Industry Context

Atai Beckley N.V. operates in the biotechnology sector, specifically focusing on psychedelic therapeutics. The acquisition of Beckley Psytech Limited strengthens Atai's portfolio and market position in this emerging and specialized field by consolidating assets and intellectual property.

Related Party Transactions

• The acquisition involved Atai Beckley N.V. acquiring the entire issued share capital of Beckley Psytech Limited not already owned by the Issuer. Given Cosmo Feilding-Mellen's role as a Director and 10% Owner of Atai, and the historical association of the Feilding-Mellen name with Beckley Psytech, this transaction likely involves related parties.

Stakeholder Impact

• Existing shareholders of Atai Beckley N.V. will experience dilution due to the issuance of 103,000,066 new common shares for the acquisition.
• Former shareholders of Beckley Psytech Limited have become shareholders of Atai Beckley N.V. as a result of the share consideration.
• The acquisition is expected to consolidate assets and intellectual property, potentially enhancing the company's long-term value for all shareholders.

Next Steps

• Vesting of 103,000 stock options on November 5, 2026.
• Monthly vesting of 40,400 stock options beginning December 5, 2025.

Key Dates

Keywords

Atai Beckley, Beckley Psytech, Acquisition, Form 4, Insider Transaction, Common Shares, Stock Options, Director, Equity, Biotechnology, Psychedelic Therapeutics